Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | BMX |
| Gene Name: | BMX |
| Protein Full Name: | Cytoplasmic tyrosine-protein kinase BMX |
| Alias: | BMX NON-receptor tyrosine kinase; Bone marrow kinase BMX; Cytoplasmic BMX; EC 2.7.10.2; Epithelial and endothelial tyrosine kinase; ETK; Kinase Etk; NTK38; Protein tyrosine kinase BMX; PSCTK3 |
| Mass (Da): | 78011 |
| Number AA: | 675 |
| UniProt ID: | P51813 |
| Locus ID: | 660 |
| COSMIC ID: | BMX |
| Gene location on chromosome: | Xp22.2 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 20104 |
| Percent of cancer specimens with mutations: | 0.58 |
| Normal role description: | Non-receptor tyrosine kinase downstream of the growth factor and interleukin pathways. Key functional role in TNF-a induced angiogenesis. BMX induces cell proliferation via STAT3 activation. BMX has been demonstrated to prevent apoptosis of nasopharyngeal carcinoma |